These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Impact of dietary iron restriction on the development of monocrotaline-induced pulmonary vascular remodeling and right ventricular failure in rats. Naito Y; Hosokawa M; Hao H; Sawada H; Hirotani S; Iwasaku T; Okuhara Y; Eguchi A; Hirota S; Ohyanagi M; Tsujino T; Masuyama T Biochem Biophys Res Commun; 2013 Jun; 436(2):145-51. PubMed ID: 23707944 [TBL] [Abstract][Full Text] [Related]
3. [Cellular signalling pathways and pathophysiology of pulmonary arterial hypertension]. Dao P; Montani D; Duong-Quy S; Dinh-Xuan AT Rev Mal Respir; 2006 Feb; 23(1 Suppl):3S75-83. PubMed ID: 16604016 [TBL] [Abstract][Full Text] [Related]
4. [Novel concepts in the pathobiology of pulmonary arterial hypertension]. Rosenkranz S Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S167-9. PubMed ID: 18814087 [TBL] [Abstract][Full Text] [Related]
5. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Yin J; Kukucka M; Hoffmann J; Sterner-Kock A; Burhenne J; Haefeli WE; Kuppe H; Kuebler WM Circ Heart Fail; 2011 Mar; 4(2):198-206. PubMed ID: 21216837 [TBL] [Abstract][Full Text] [Related]
6. Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. Leopold JA; Maron BA Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213345 [TBL] [Abstract][Full Text] [Related]
7. Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension. Berghausen E; ten Freyhaus H; Rosenkranz S Handb Exp Pharmacol; 2013; 218():381-408. PubMed ID: 24092349 [TBL] [Abstract][Full Text] [Related]
8. [Pulmonary hypertension: from molecular pathophysiology to haemodynamic abnormalities]. Duong-Quy S; Rivière S; Bei Y; Duong-Ngo C; Le-Dong NN; Hua-Huy T; Dinh-Xuan AT Rev Mal Respir; 2012 Oct; 29(8):956-70. PubMed ID: 23101638 [TBL] [Abstract][Full Text] [Related]
9. Reactive oxygen species as therapeutic targets in pulmonary hypertension. Freund-Michel V; Guibert C; Dubois M; Courtois A; Marthan R; Savineau JP; Muller B Ther Adv Respir Dis; 2013 Jun; 7(3):175-200. PubMed ID: 23328248 [TBL] [Abstract][Full Text] [Related]
11. Pathophysiology and clinical relevance of pulmonary remodelling in pulmonary hypertension due to left heart diseases. Dupuis J; Guazzi M Can J Cardiol; 2015 Apr; 31(4):416-29. PubMed ID: 25840093 [TBL] [Abstract][Full Text] [Related]
12. Right ventricular electrical remodeling and arrhythmogenic substrate in rat pulmonary hypertension. Tanaka Y; Takase B; Yao T; Ishihara M Am J Respir Cell Mol Biol; 2013 Sep; 49(3):426-36. PubMed ID: 23600532 [TBL] [Abstract][Full Text] [Related]
13. Animal models related to congenital heart disease and clinical research in pulmonary hypertension. Loukanov T; Geiger R; Agrawal R Cardiology; 2010; 116(1):18-25. PubMed ID: 20424448 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Pullamsetti SS; Doebele C; Fischer A; Savai R; Kojonazarov B; Dahal BK; Ghofrani HA; Weissmann N; Grimminger F; Bonauer A; Seeger W; Zeiher AM; Dimmeler S; Schermuly RT Am J Respir Crit Care Med; 2012 Feb; 185(4):409-19. PubMed ID: 22161164 [TBL] [Abstract][Full Text] [Related]